What is the maximum daily dose?

The maximum dose is 40 ml/kg/day, equivalent to 0.88 g of amino acids and 3.2 g of glucose.

Where are the products exported to?

Products are sold to countries and regions in South America, Africa, Asia, and Oceania.

Lipid Emulsion 10% /Amino Acids 15 and Glucose 20% Injection

Name: Lipid Emulsion 10% /Amino Acids 15 and Glucose 20% Injection
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2092154672

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.80-1.20

10,000 Pieces

Sample price:US$2.60/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Injection

Suitable for

Elderly, Adult

State

Liquid

Shape

Injection

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Transport Package

Carton

Specification

1000ml

Trademark

SHIMEN

Origin

China

HS Code

3004909099

Production Capacity

10000000

Key features

Triple Chamber Bag Design: Contains fat emulsion, amino acids, and glucose in a single three-chamber bag.

Parenteral Nutrition Solution: Ideal for patients when oral or enteral nutrition is unavailable or contraindicated.

Wide Age Applicability: Suitable for intravenous infusion in children over 2 years of age and adults.

Flexible Dosage Options: Available in 500ml, 250ml, and 100ml soft plastic bottle specifications.

GMP Certified Manufacturing: Produced by a large enterprise with SFDA GMP approval and over 3000 employees.

Global Market Reach: Products exported to South America, Africa, Asia, and other international regions.

High Production Capacity: Yearly output exceeds 1200 million bottles of large volume I.V solutions.

Established Manufacturer: Shijiazhuang No.4 Pharmaceutical Co., Ltd. established in 1948 with USD 58 million capital.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤24hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.